Answers are grounded in this paper and cite their sources.
Case report shows safe Methotrexate use in a psoriasis patient with mild hepatotoxicity, suggesting FIB-4 can monitor liver risk.
Introduction : Methotrexate is often used as the first line of systemic treatment in patients with moderate to severe psoriasis and psoriatic arthritis. Case report : We present the case of a 44-year-old male patient with moderate plaque psoriasis who was treated with Methotrexate and diagnosed with mild hepatic steatosis during the first month of treatment. Using FIB-4 (Fibrosis Index Based on 4 factors) as a noninvasive method for assessing the risk of liver fibrosis, the patient was able to take Methotrexate safely, with close monitoring of liver function. Conclusions : FIB-4 can be used to assess the risk of liver fibrosis in psoriasis patients treated with Methotrexate to ensure better adherence to the treatment.
No takes yet. Share an insight, caveat, or question.
Sandu et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: